14 completed, 6 terminated, 3 active not recruiting, 2 unknown. 26 Phase 2, 6 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 26 | Completed 14, Terminated 6, Active not recruiting 3, Unknown 2, Recruiting 1 |
| Phase 1 | 6 | Terminated 3, Completed 2, Active not recruiting 1 |
Follow bosutinib: new trials by email Literature Review of bosutinib trials Research Report on bosutinib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety and Efficacy Evaluation of Bosutinib Plus Atezolizumab in Newly Diagnosed Chronic Leukemia Adult Patients Bosutinib 400 MG Monotherapy, Bosutinib 400 MG + Atezolizumab 840 MG in 14 ML Injection - Chronic Phase-Chronic Myeloid Leukemia | Phase 1 / Phase 2 | Terminated | Fundacion Espanola para la Curacion de la Leucemia Mieloide Cronica | 9 | 2021-02-24 | 2024-03-19 |
| Safety And Efficacy Of TKI Cessation For CML Patients With Stable Molecular Response In A Real World Population Imatinib Mesylate, Dasatinib, Nilotinib or Bosutinib Withdrawal, Imatinib Mesylate, Dasatinib, Nilotinib or Bosutinib Re-initiation - Chronic Myeloid Leukemia, Chronic Myeloid Leukemia, BCR/ABL-Positive, in Remission | Phase 2 | Active not recruiting | Baylor College of Medicine | 17 | 2020-12-22 | 2026-05-04 |
| Omega -3 Fatty Acid in Combination With Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia Eicosapentaenoic Acid, Tyrosine kinase inhibitor - Chronic Myeloid Leukemia, Chronic Phase | Phase 1 / Phase 2 | Terminated | Milton S. Hershey Medical Center | 1 | 2020-09-14 | 2022-07-01 |
| Bosutinib in Pediatric Patients With Newly Diagnosed Chronic Phase or Resistant/Intolerant Ph + Chronic Myeloid Leukemia Bosutinib - Philadelphia Chromosome Positive CML, Accelerated Phase Chronic Myelogenous Leukemia | Phase 1 / Phase 2 | Active not recruiting | Children's Oncology Group | 60 | 2020-07-06 | 2026-10-01 |
| A Study of REduction And DIscontinuation Treatment of TKI (Imatinib, Nilotinib, Dasatinib and Bosutinib) Imatinib, Nilotinib, Dasatinib - Chronic Myeloid Leukemia, Chronic Myeloid Leukemia in Remission | Phase 2 | Unknown | National Research Center for Hematology, Russia | 100 | 2020-01-15 | 2020-10-08 |
| Impact of Bosutinib on Safety, Tolerability, Biomarkers and Clinical Outcomes in Dementia With Lewy Bodies Placebo Oral Tablet, Bosutinib Oral Tablet - Dementia With Lewy Bodies | Phase 2 | Completed | Georgetown University | 26 | 2019-04-23 | 2026-07-10 |
| Long-acting Low Dose Ropeginterferon for Chronic Myeloid Leukemia Treated With Bosutinib From Diagnosis Bosutinib, Ropeginterferon - Chronic Myeloid Leukemia | Phase 2 | Completed | St. Olavs Hospital | 212 | 2019-03-25 | 2025-06-08 |
| iPSC-based Drug Repurposing for ALS Medicine (iDReAM) Study Bosutinib (Phase 1 part), Bosutinib (Phase 2 part) - Amyotrophic Lateral Sclerosis | Phase 1 / Phase 2 | Completed | Kyoto University | 46 | 2019-03-19 | 2026-08-10 |
| Testing the Addition of Ruxolitinib to the Usual Treatment (Tyrosine Kinase Inhibitors) for Chronic Myeloid Leukemia Bosutinib, Dasatinib, Laboratory Biomarker Analysis - Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Phase 2 | Active not recruiting | SWOG Cancer Research Network | 81 | 2018-10-24 | 2025-12-18 |
| Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR) Olaparib, Dasatinib, Nivolumab plus Ipilimumab - Lymphoma, Non-Hodgkin, Multiple Myeloma | Phase 2 | Recruiting | Canadian Cancer Trials Group | 720 | 2018-03-23 | 2026-03-27 |
| Study of Bosutinib in Japanese Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia Bosutinib - Leukemia, Chronic Myelogenous | Phase 2 | Completed | Pfizer | 64 | 2017-05-15 | 2022-05-19 |
| Bosutinib in Elderly Chronic Myeloid Leukemia Bosutinib - Chronic Myeloid Leukemia | Phase 2 | Completed | Gruppo Italiano Malattie EMatologiche dell'Adulto | 65 | 2016-11-17 | 2023-02-03 |
| Bosutinib in Treating Patients With Chronic Myeloid Leukemia in Chronic Phase After Frontline TKI Failure Bosutinib, Laboratory Biomarker Analysis - Blasts Under 15 Percent of Bone Marrow Nucleated Cells, Blasts Under 15 Percent of Peripheral Blood White Cells | Phase 2 | Terminated | M.D. Anderson Cancer Center | 8 | 2016-10-28 | 2020-05-11 |
| Phase II Study Testing the Tolerability and the Efficacy of Bosutinib in Chronic Phase CML Patients Bosulif - Chronic Myelogenous Leukaemia | Phase 2 | Unknown | University of Bonn | 127 | 2016-03-01 | 2017-07-02 |
| Allogeneic Stem Cell Transplantation in Chronic Myeloid Leukemia Failing TKIs Therapy Bosutinib, Bone Marrow Transplant, Bone Marrow cells - Leukemia, Myelogenous | Phase 2 | Completed | University of Milano Bicocca | 2 | 2015-11-01 | 2020-11-05 |
| CML Treated With Bosutinib After Relapse Bosutinib - Chronic Myeloblastic Leukaemia | Phase 2 | Completed | PETHEMA Foundation | 30 | 2015-05-01 | 2020-04-29 |
| Phase I/II Study of Bosutinib in Combination With Inotuzumab Ozogamicin in CD22-positive PC Positive ALL and CML Bosutinib, Inotuzumab Ozogamicin - B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Phase 1 / Phase 2 | Completed | M.D. Anderson Cancer Center | 22 | 2015-04-16 | 2023-07-17 |
| The Life After Stopping Tyrosine Kinase Inhibitors Study (The LAST Study) Imatinib (Stopping their TKI), Dasatinib (Stopping their TKI), Nilotinib (Stopping their TKI) - Leukemia, Myeloid, Chronic | Phase 2 | Completed | Medical College of Wisconsin | 173 | 2014-12-18 | 2023-03-03 |
| Bosutinib in Adult Patients With Recurrent Glioblastoma bosutinib - Glioblastoma | Phase 2 | Completed | Massachusetts General Hospital | 36 | 2011-04-01 | 2016-07-25 |
| Bosutinib For Autosomal Dominant Polycystic Kidney Disease Bosutinib, Placebo - Polycystic Kidney, Autosomal Dominant | Phase 2 | Completed | Pfizer | 172 | 2010-12-01 | 2016-03-11 |
Showing 20 of 26. Sign in to see all of them.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive (11) · Leukemia, Myeloid, Chronic-Phase (5) · Breast Neoplasms (3) · Blast Crisis (2) · Leukemia (2) · Amyotrophic Lateral Sclerosis (1) · Bronchiolitis Obliterans Syndrome (1) · Glioblastoma (1) · Leukemia, Myeloid, Accelerated Phase (1) · Lewy Body Disease (1) · Lymphoma, Non-Hodgkin (1) · Multiple Myeloma (1) · Neoplasm Metastasis (1) · Philadelphia Chromosome (1) · Polycystic Kidney, Autosomal Dominant (1)
Pfizer (8) · M.D. Anderson Cancer Center (2) · Baylor College of Medicine (1) · Canadian Cancer Trials Group (1) · Children's Oncology Group (1) · Fundacion Espanola para la Curacion de la Leucemia Mieloide Cronica (1) · Georgetown University (1) · Gruppo Italiano Malattie EMatologiche dell'Adulto (1) · Kyoto University (1) · Massachusetts General Hospital (1) · Medical College of Wisconsin (1) · Milton S. Hershey Medical Center (1) · National Research Center for Hematology, Russia (1) · PETHEMA Foundation (1) · SWOG Cancer Research Network (1)
United States (15) · Spain (7) · Australia (5) · Hong Kong (5) · Italy (5) · Canada (4) · Hungary (4) · Poland (4) · Belgium (3) · China (3) · France (3) · Germany (3) · Japan (3) · Russia (3) · Sweden (3)
Anna Turkina, Professor (1) · Carlo Gambacorti-Passerini, MD (1) · Daniel J Renouf (1) · Dominik GF Wolf, Prof. Dr. (1) · Ehab Atallah, MD (1) · Fausto Castagnetti (1) · Fernando L Pagan, MD (1) · Haruhisa Inoue (1) · Henrik Hjorth-Hansen, md phd (1) · Kathryn Flynn, PhD (1) · Kendra L Sweet (1) · Lillian Siu (1) · Luis Felipe Casado, Dr (1)
PMID 35235189, PMID 21865346, PMID 22036634, PMID 22371878, PMID 23116602, PMID 24345751, PMID 24674873, PMID 24674874, PMID 24711212, PMID 24919837, PMID 25290090, PMID 25540064, PMID 25635231, PMID 27045164, PMID 27531525, PMID 28409328, PMID 28838955, PMID 29072772, PMID 29609532, PMID 29773593, PMID 32279228, PMID 33180106, PMID 33513367, PMID 34673442, PMID 35963986, PMID 36467452, PMID 37553873, PMID 38033284, PMID 39356039, PMID 39461864
2005 (1), 2008 (1), 2014 (1), 2015 (1), 2016 (1), 2018 (1), 2023 (1), P30CA016672 (1), U10CA180888 (1)